• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于补偿药物发现方法中偏差的热力学替代指标

Thermodynamic Proxies to Compensate for Biases in Drug Discovery Methods.

作者信息

Ekins Sean, Litterman Nadia K, Lipinski Christopher A, Bunin Barry A

机构信息

Collaborative Drug Discovery, Inc., 1633 Bayshore Highway Suite 342, Burlingame, California, 94010, USA.

Collaborations in Chemistry, 5616 Hilltop Needmore Road, Fuquay Varina, North Carolina, 27526, USA.

出版信息

Pharm Res. 2016 Jan;33(1):194-205. doi: 10.1007/s11095-015-1779-y. Epub 2015 Aug 27.

DOI:10.1007/s11095-015-1779-y
PMID:26311555
Abstract

PURPOSE

We propose a framework with simple proxies to dissect the relative energy contributions responsible for standard drug discovery binding activity.

METHODS

We explore a rule of thumb using hydrogen-bond donors, hydrogen-bond acceptors and rotatable bonds as relative proxies for the thermodynamic terms. We apply this methodology to several datasets (e.g., multiple small molecules profiled against kinases, Mycobacterium tuberculosis (Mtb) high throughput screening (HTS) and structure based drug design (SBDD) derived compounds, and FDA approved drugs).

RESULTS

We found that Mtb active compounds developed through SBDD methods had statistically significantly larger PEnthalpy values than HTS derived compounds, suggesting these compounds had relatively more hydrogen bond donor and hydrogen bond acceptors compared to rotatable bonds. In recent FDA approved medicines we found that compounds identified via target-based approaches had a more balanced enthalpic relationship between these descriptors compared to compounds identified via phenotypic screens

CONCLUSIONS

As it is common to experimentally optimize directly for total binding energy, these computational methods provide alternative calculations and approaches useful for compound optimization alongside other common metrics in available software and databases.

摘要

目的

我们提出了一个带有简单代理变量的框架,以剖析对标准药物发现结合活性起作用的相对能量贡献。

方法

我们探索了一种经验法则,使用氢键供体、氢键受体和可旋转键作为热力学项的相对代理变量。我们将此方法应用于多个数据集(例如,针对激酶进行分析的多个小分子、结核分枝杆菌(Mtb)高通量筛选(HTS)和基于结构的药物设计(SBDD)衍生的化合物,以及美国食品药品监督管理局(FDA)批准的药物)。

结果

我们发现,通过SBDD方法开发的Mtb活性化合物的PEnthalpy值在统计学上显著高于HTS衍生的化合物,这表明与可旋转键相比,这些化合物具有相对更多的氢键供体和氢键受体。在最近FDA批准的药物中,我们发现与通过表型筛选鉴定的化合物相比,通过基于靶点的方法鉴定的化合物在这些描述符之间具有更平衡的焓关系。

结论

由于直接针对总结合能进行实验优化很常见,这些计算方法提供了替代计算和方法,可与现有软件和数据库中的其他常见指标一起用于化合物优化。

相似文献

1
Thermodynamic Proxies to Compensate for Biases in Drug Discovery Methods.用于补偿药物发现方法中偏差的热力学替代指标
Pharm Res. 2016 Jan;33(1):194-205. doi: 10.1007/s11095-015-1779-y. Epub 2015 Aug 27.
2
Why are membrane targets discovered by phenotypic screens and genome sequencing in Mycobacterium tuberculosis?为什么在结核分枝杆菌中通过表型筛选和基因组测序发现膜靶标?
Tuberculosis (Edinb). 2013 Nov;93(6):569-88. doi: 10.1016/j.tube.2013.09.003. Epub 2013 Sep 18.
3
Enhancing hit identification in Mycobacterium tuberculosis drug discovery using validated dual-event Bayesian models.利用经过验证的双事件贝叶斯模型提高结核分枝杆菌药物发现中的命中鉴定。
PLoS One. 2013 May 7;8(5):e63240. doi: 10.1371/journal.pone.0063240. Print 2013.
4
A collaborative database and computational models for tuberculosis drug discovery.用于结核病药物研发的协作数据库和计算模型。
Mol Biosyst. 2010 May;6(5):840-51. doi: 10.1039/b917766c. Epub 2010 Feb 9.
5
Validating new tuberculosis computational models with public whole cell screening aerobic activity datasets.用公共全细胞筛选需氧活性数据集验证新的结核病计算模型。
Pharm Res. 2011 Aug;28(8):1859-69. doi: 10.1007/s11095-011-0413-x. Epub 2011 Mar 10.
6
Combining computational methods for hit to lead optimization in Mycobacterium tuberculosis drug discovery.结合计算方法用于结核分枝杆菌药物发现中从活性分子到先导化合物的优化
Pharm Res. 2014 Feb;31(2):414-35. doi: 10.1007/s11095-013-1172-7. Epub 2013 Oct 17.
7
Analysis and hit filtering of a very large library of compounds screened against Mycobacterium tuberculosis.针对结核分枝杆菌筛选的超大型化合物库的分析与活性筛选
Mol Biosyst. 2010 Nov;6(11):2316-2324. doi: 10.1039/c0mb00104j. Epub 2010 Sep 8.
8
A High Throughput Screening Assay for Anti-Mycobacterial Small Molecules Based on Adenylate Kinase Release as a Reporter of Cell Lysis.一种基于腺苷酸激酶释放作为细胞裂解报告物的抗分枝杆菌小分子高通量筛选测定法。
PLoS One. 2015 Jun 22;10(6):e0129234. doi: 10.1371/journal.pone.0129234. eCollection 2015.
9
Cheminformatics approaches to analyze diversity in compound screening libraries.化学信息学方法分析化合物筛选库中的多样性。
Curr Opin Chem Biol. 2010 Jun;14(3):325-30. doi: 10.1016/j.cbpa.2010.03.017. Epub 2010 Apr 22.
10
Recent progress in fragment-based lead discovery.基于片段的先导化合物发现的最新进展。
Curr Opin Pharmacol. 2009 Oct;9(5):615-21. doi: 10.1016/j.coph.2009.04.009. Epub 2009 May 27.

引用本文的文献

1
Structural and Thermodynamic Basis of the Enhanced Interaction between Kinesin Spindle Protein Eg5 and STLC-type Inhibitors.驱动蛋白纺锤体蛋白Eg5与STLC型抑制剂之间增强相互作用的结构和热力学基础
ACS Omega. 2018 Sep 28;3(9):12284-12294. doi: 10.1021/acsomega.8b00778. eCollection 2018 Sep 30.
2
Data Mining and Computational Modeling of High-Throughput Screening Datasets.高通量筛选数据集的数据挖掘与计算建模
Methods Mol Biol. 2018;1755:197-221. doi: 10.1007/978-1-4939-7724-6_14.
3
The Next Era: Deep Learning in Pharmaceutical Research.

本文引用的文献

1
Open Source Bayesian Models. 1. Application to ADME/Tox and Drug Discovery Datasets.开源贝叶斯模型。1. 在药物代谢动力学/药物毒性及药物发现数据集方面的应用
J Chem Inf Model. 2015 Jun 22;55(6):1231-45. doi: 10.1021/acs.jcim.5b00143. Epub 2015 Jun 3.
2
Applying thermodynamic profiling in lead finding and optimization.应用热力学分析进行先导化合物发现和优化。
Nat Rev Drug Discov. 2015 Feb;14(2):95-110. doi: 10.1038/nrd4486. Epub 2015 Jan 23.
3
The use of thermodynamic and kinetic data in drug discovery: decisive insight or increasing the puzzlement?
下一个时代:药物研究中的深度学习。
Pharm Res. 2016 Nov;33(11):2594-603. doi: 10.1007/s11095-016-2029-7. Epub 2016 Sep 6.
4
"Zipped Synthesis" by Cross-Metathesis Provides a Cystathionine β-Synthase Inhibitor that Attenuates Cellular H2S Levels and Reduces Neuronal Infarction in a Rat Ischemic Stroke Model.“拉链合成”通过交叉复分解提供半胱氨酸 β-合酶抑制剂,可降低细胞内 H2S 水平并减少大鼠缺血性中风模型中的神经元梗死。
ACS Cent Sci. 2016 Apr 27;2(4):242-52. doi: 10.1021/acscentsci.6b00019. Epub 2016 Mar 9.
热力学和动力学数据在药物发现中的应用:决定性见解还是增加困惑?
ChemMedChem. 2015 Feb;10(2):229-31. doi: 10.1002/cmdc.201402521. Epub 2014 Dec 23.
4
Is there a link between selectivity and binding thermodynamics profiles?选择性和结合热力学特征之间是否存在关联?
Drug Discov Today. 2015 Jan;20(1):86-94. doi: 10.1016/j.drudis.2014.09.014. Epub 2014 Sep 27.
5
Chemistry: Chemical con artists foil drug discovery.化学:化学骗子阻碍药物研发。
Nature. 2014 Sep 25;513(7519):481-3. doi: 10.1038/513481a.
6
Genome editing-enabled HTS assays expand drug target pathways for Charcot-Marie-tooth disease.基于基因组编辑的高通量筛选分析扩展了腓骨肌萎缩症的药物靶点途径。
ACS Chem Biol. 2014 Nov 21;9(11):2594-602. doi: 10.1021/cb5005492. Epub 2014 Sep 16.
7
The importance of hydration thermodynamics in fragment-to-lead optimization.水合热力学在片段到先导物优化中的重要性。
ChemMedChem. 2014 Dec;9(12):2708-17. doi: 10.1002/cmdc.201402207. Epub 2014 Aug 27.
8
Applications of structure-based design to antibacterial drug discovery.基于结构的设计在抗菌药物研发中的应用。
Bioorg Chem. 2014 Aug;55:69-76. doi: 10.1016/j.bioorg.2014.05.008. Epub 2014 Jun 2.
9
Ligand efficiency metrics considered harmful.被认为有害的配体效率指标。
J Comput Aided Mol Des. 2014 Jul;28(7):699-710. doi: 10.1007/s10822-014-9757-8. Epub 2014 Jun 5.
10
Current progress in Structure-Based Rational Drug Design marks a new mindset in drug discovery.基于结构的合理药物设计的当前进展标志着药物发现领域的一种新思维方式。
Comput Struct Biotechnol J. 2013 Apr 2;5:e201302011. doi: 10.5936/csbj.201302011. eCollection 2013.